Jazz Pharma director reports tax share withholding

Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related share disposition.

Accepted by SEC EDGAR 03/09/2026 - 05:31 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 15,114 Ordinary Shares were withheld at $188.69 per share to satisfy tax obligations, reducing his directly held stake to 390,682 Ordinary Shares. This Form 4 reflects a tax-withholding transaction rather than an open-market trade.

Insider Trade Summary

Exercise Price or Tax Liability: 15,114 shares

Exercise Price or Tax Liability 1 txn

Insider COZADD BRUCE C

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	15,114	$188.69	$2.85M

Holdings After Transaction: Ordinary Shares — 390,682 shares (Direct)

Holdings Before and After: Ordinary Shares, 405,796 to 390,682 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Bruce C. Cozadd?

Jazz Pharmaceuticals reported that director Bruce C. Cozadd had 15,114 Ordinary Shares withheld to cover taxes from vesting restricted stock units. The shares were valued at $188.69 each, and the transaction is classified as a tax-withholding disposition, not an open-market trade.

How many Jazz Pharmaceuticals (JAZZ) shares were involved in Bruce Cozadd’s Form 4 filing?

The Form 4 shows 15,114 Ordinary Shares of Jazz Pharmaceuticals were withheld. These shares were used to satisfy tax obligations triggered by the vesting of restricted stock units, rather than being sold on the open market or acquired in a new purchase.

What was the price per share in Bruce Cozadd’s Jazz Pharmaceuticals (JAZZ) tax-withholding transaction?

The shares in Bruce Cozadd’s tax-withholding transaction were valued at $188.69 per Ordinary Share. This value applies to the 15,114 shares withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.

How many Jazz Pharmaceuticals (JAZZ) shares does Bruce Cozadd hold after this Form 4 transaction?

After the tax-withholding disposition, Bruce Cozadd directly holds 390,682 Ordinary Shares of Jazz Pharmaceuticals. This figure reflects his remaining direct ownership following the withholding of 15,114 shares to cover tax obligations on vesting restricted stock units.

Was Bruce Cozadd’s Jazz Pharmaceuticals (JAZZ) Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. The Form 4 and its footnote state that 15,114 shares were withheld solely to satisfy tax obligations from vesting restricted stock units, classifying it as a tax-withholding disposition rather than a discretionary sale.

What does transaction code F mean in Bruce Cozadd’s Jazz Pharmaceuticals (JAZZ) Form 4?

Transaction code F indicates payment of a tax liability or exercise price by delivering securities. In this case, 15,114 Jazz Pharmaceuticals Ordinary Shares were withheld to cover tax obligations from the vesting of restricted stock units, instead of being sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/05/2026		F(1)		15,114	D	$188.69	390,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.